First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01
Toshio Shimizu(Wakayama Medical University), Rebecca S. Heist(Massachusetts General Hospital), Noboru Yamamoto(Tokyo National Hospital), Alexander I. Spira(Virginia Cancer Specialists), Melissa L. Johnson(Tennessee Oncology), Kiyotaka Yoh(National Cancer Center Hospital East), Jacob Sands(Harvard University), Satoru Kitazono(The Cancer Institute Hospital), Edward B. Garon(University of California, Los Angeles), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Penny Phillips(Daiichi Sankyo (United States)), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Aaron Lisberg(APLA Health), Hong Zebger‐Gong(Daiichi Sankyo (Germany)), Jon Greenberg(Daiichi Sankyo (Germany)), Fumiaki Kobayashi(Daiichi-Sankyo (Japan)), Yui Kawasaki(Daiichi Sankyo (United States))
Cited by 168
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k